Commonwealth Equity Services LLC Raises Stake in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE)

Commonwealth Equity Services LLC increased its stake in shares of iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Get Rating) by 9.5% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 13,332 shares of the company’s stock after purchasing an additional 1,157 shares during the period. Commonwealth Equity Services LLC owned 0.59% of iShares U.S. Pharmaceuticals ETF worth $2,481,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in IHE. Wells Fargo & Company MN increased its stake in iShares U.S. Pharmaceuticals ETF by 14.5% in the 2nd quarter. Wells Fargo & Company MN now owns 71,446 shares of the company’s stock worth $13,693,000 after acquiring an additional 9,033 shares during the last quarter. Royal Bank of Canada increased its stake in iShares U.S. Pharmaceuticals ETF by 11.5% in the 3rd quarter. Royal Bank of Canada now owns 45,847 shares of the company’s stock worth $7,772,000 after acquiring an additional 4,726 shares during the last quarter. Bank of America Corp DE increased its stake in iShares U.S. Pharmaceuticals ETF by 26.3% in the 1st quarter. Bank of America Corp DE now owns 42,640 shares of the company’s stock worth $8,284,000 after acquiring an additional 8,892 shares during the last quarter. Fisher Asset Management LLC increased its stake in iShares U.S. Pharmaceuticals ETF by 77.2% in the 4th quarter. Fisher Asset Management LLC now owns 38,725 shares of the company’s stock worth $7,208,000 after acquiring an additional 16,875 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of iShares U.S. Pharmaceuticals ETF by 255.7% during the 2nd quarter. Goldman Sachs Group Inc. now owns 29,594 shares of the company’s stock valued at $5,672,000 after purchasing an additional 21,275 shares during the last quarter.

iShares U.S. Pharmaceuticals ETF Trading Down 0.3 %

Shares of iShares U.S. Pharmaceuticals ETF stock opened at $178.06 on Tuesday. The firm has a market capitalization of $382.83 million, a PE ratio of 16.27 and a beta of 0.70. The business’s 50-day moving average price is $177.90 and its 200-day moving average price is $181.82. iShares U.S. Pharmaceuticals ETF has a 12 month low of $166.99 and a 12 month high of $197.28.

iShares U.S. Pharmaceuticals ETF Profile

(Get Rating)

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.